Survival of Triple Negative versus Triple Positive Breast Cancers: Comparison and Contrast |
Negi, Preety
(Department of Radiation Oncology, Christian Medical College & Hospital)
Kingsley, Pamela Alice (Department of Radiation Oncology, Christian Medical College & Hospital) Jain, Kunal (Department of Medical Oncology, Christian Medical College & Hospital) Sachdeva, Jaineet (Department of Radiation Oncology, Christian Medical College & Hospital) Srivastava, Himanshu (Department of Radiation Oncology, Rajiv Gandhi Cancer Institute & Research Centre) Marcus, Sudeep (Department of Radiation Oncology, Christian Medical College & Hospital) Pannu, Aman (Department of Neurology, Christian Medical College & Hospital) |
1 | Onitilo AA, Engel JM, Greenlee RT, Mukesh BN (2009). Breast cancer subtypes based on ER / PR and Her-2 overexpression: comparison of clinicopathologic features and survival. Clin Med Res, 7, 4-13. DOI |
2 | Osako T, Nishimura R, Okumura Y, Arima N (2008). Premenopausal status reflects an unfavourable prognosis in triple-negative breast cancer. J Clinic Oncol, ASCO Annual Meeting Proceedings, 26, 222. |
3 | Ovcaricek T, Frkovic SG, Matos E, Mozina B, Borstnar S (2011). Triple negative breast cancer- prognostic factors and survival. Radiol Oncol, 45, 46-52. |
4 | Sajid MT, Ahmed M, Azhar M, et al (2014). Age-related frequency of triple negative breast cancer in women. J Coll Physicians Surg Pak, 24, 400-3. |
5 | Sandhu R, Parker JS, Jones WD, Livasy CA, Coleman WB (2010). Microarray-based gene expression profiling for molecular classification of breast cancer and identification of new targets for therapy. Lab Med, 41, 364-72. DOI |
6 | Sorlie T, Perou CM, Tibshirani R, et al (2001). Gene expression patterns of breast carcinomas distinguish tumour subclasses with clinical implications. Proc Natl Acad Sci USA, 98, 10869-74. DOI |
7 | Sorlie T, Tibshirani R, Parker J, et al (2003). Repeated observation of breast tumour subtypes in independent gene expression data sets. Proc Natl Acad Sci USA, 100, 8418-23. DOI |
8 | Vici P, Pizzuti L, Natoli C, et al (2015). Triple positive breast cancer: A distinct subtype? Cancer Treat Rev, 41, 69-76. DOI |
9 | Yin W, Jiang Y, Shen Z, Shao Z, Lu J (2011). Trastuzumab in the adjuvant treatment of HER-2 positive early breast cancer patients: a meta-analysis of published randomized controlled trials. PLoS One, 6, 21030. DOI |
10 | Ades F, Zardavas D, Bozovic-Spasojevic I, et al (2014). Luminal B breast cancer: Molecular characterization, clinical management, and future perspectives. J Clin Oncol, 32, 2794-803. DOI |
11 | Ahmad A (2013). Pathways to breast cancer recurrence. ISRN Oncol, 290568. |
12 | Allison KH (2012). Molecular pathology of breast cancer. Am J Clin Pathol, 138, 770-80. DOI |
13 | Giordano SH, Temin S, Kirshner JJ, et al (2014). Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol, 32, 2078-99. DOI |
14 | Brouckaert O, Wildiers H, Floris G, Neven P (2012). Update on triple-negative breast cancer: prognosis and management strategies. Int J Womens Health, 4, 511-20. |
15 | Carey LA, Perou CM, Livasy CA, et al (2006). Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA, 295, 2492-502. DOI |
16 | Dent R, Trudeau M, Pritchard KI, et al (2007). Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res, 13, 4429-34. DOI |
17 | Lara-Medina F, Perez-Sanchez V, Saavedra-Perez D, et al (2011). Triple-negative breast cancer in Hispanic patients: high prevalence, poor prognosis, and association with menopausal status, body mass index, and parity. Cancer, 117, 3658-69. DOI |
18 | Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn HJ (2009). Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol, 20,1319-29. DOI |
19 | Hudis CA and Gianni L (2011). Triple negative breast cancer: an unmet medical need. Oncologist, 16, 1-11. |
20 | Jack RH, Davies EA, Renshaw C, et al (2013). Differences in breast cancer hormone receptor status in ethnic groups: a London population. Eur J Cancer, 49, 696-702. DOI |
21 | Morris GJ, Naidu S, Topham AK, et al (2007). Differences in breast carcinoma characteristics in newly diagnosed African- American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute’s Surveillance, Epidemiology, and End Results database. Cancer, 110, 876-84. DOI |